Role of GPX4-Mediated Ferroptosis in the Sensitivity of Triple Negative Breast Cancer Cells to Gefitinib

Overview

Journal Front Oncol

Specialty Oncology

Date 2021 Jan 11

PMID 33425751

Citations 68

Authors

Xiang Song

Xinzhao Wang

Zhaoyun Liu

Zhiyong Yu

Affiliations

Soon will be listed here.

Abstract

Gefitinib resistance in triple negative breast cancer (TNBC) is a growing important concern. Glutathione peroxidase 4 (GPX4) is a main regulator of ferroptosis, which is pivotal for TNBC cell growth. We investigated GPX4-mediated ferroptosis in gefitinib sensitivity in TNBC. Gefitinib resistant TNBC cells MDA-MB-231/Gef and HS578T/Gef were constructed and treated with lentivirus sh-GPX4 and ferroptosis inhibitor ferrostatin-1. GPX4 expression, cell viability and apoptosis were detected. Malondialdehyde (MDA), glutathione (GSH), reactive oxygen species (ROS) levels were evaluated. The levels of ferroptosis-related proteins were detected. Subcutaneous tumor model was established in nude mice, and gefitinib was intraperitoneally injected to evaluate tumor growth, apoptosis, and Ki-67 expression. GPX4 was increased in gefitinib-resistant cells. After silencing GPX4, the inhibition rate of cell viability was increased, the limitation of colony formation ability was reduced, apoptosis rate was increased, and the sensitivity of cells to gefitinib was improved. After silencing GPX4, MDA and ROS production were increased, while GSH was decreased. Silencing GPX4 promoted ferroptosis. Inhibition of GPX4 promoted gefitinib sensitivity by promoting cell ferroptosis. experiments also revealed that inhibition of GPX4 enhanced the anticancer effect of gefitinib through promoting ferroptosis. Overall, inhibition of GPX4 stimulated ferroptosis and enhanced TNBC cell sensitivity to gefitinib.

Citing Articles

Yang Y, Yu S, Liu W, Zhuo Y, Qu C, Zeng Y Cancer Drug Resist. 2025; 8:1.

PMID: 39935430 PMC: 11813627. DOI: 10.20517/cdr.2024.151.

Targeting ferroptosis: a promising strategy to overcome drug resistance in breast cancer.

Peng C, Chen Y, Jiang M Front Oncol. 2025; 14:1499125.

PMID: 39759144 PMC: 11695291. DOI: 10.3389/fonc.2024.1499125.

STT3-mediated aberrant N-glycosylation of CD24 inhibits paclitaxel sensitivity in triple-negative breast cancer.

Wang J, Zhang H, Zhu G, Zhao L, Shi J, Dai Z Acta Pharmacol Sin. 2024; .

PMID: 39668180 DOI: 10.1038/s41401-024-01419-0.

Broadening horizons: the multifaceted role of ferroptosis in breast cancer.

Ge A, Xiang W, Li Y, Zhao D, Chen J, Daga P Front Immunol. 2024; 15:1455741.

PMID: 39664391 PMC: 11631881. DOI: 10.3389/fimmu.2024.1455741.

Assessment of ferroptosis as a promising candidate for metastatic uveal melanoma treatment and prognostication.

Swords E, Kennedy B, Tonelotto V Front Pharmacol. 2024; 15:1466896.

PMID: 39411069 PMC: 11473310. DOI: 10.3389/fphar.2024.1466896.

References

Giordano C, Mueller K, Terlecky L, Krentz K, Bollig-Fischer A, Terlecky S . A targeted enzyme approach to sensitization of tyrosine kinase inhibitor-resistant breast cancer cells. Exp Cell Res. 2012; 318(16):2014-21. PMC: 3858180. DOI: 10.1016/j.yexcr.2012.06.001. View

Li X, Wang T, Huang X, Li Y, Sun T, Zang S . Targeting ferroptosis alleviates methionine-choline deficient (MCD)-diet induced NASH by suppressing liver lipotoxicity. Liver Int. 2020; 40(6):1378-1394. DOI: 10.1111/liv.14428. View

McGovern U, Francis R, Peck B, Guest S, Wang J, Myatt S . Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer. Mol Cancer Ther. 2009; 8(3):582-91. DOI: 10.1158/1535-7163.MCT-08-0805. View

Jelinek A, Heyder L, Daude M, Plessner M, Krippner S, Grosse R . Mitochondrial rescue prevents glutathione peroxidase-dependent ferroptosis. Free Radic Biol Med. 2018; 117:45-57. DOI: 10.1016/j.freeradbiomed.2018.01.019. View

Nirmala J, Lopus M . Cell death mechanisms in eukaryotes. Cell Biol Toxicol. 2019; 36(2):145-164. DOI: 10.1007/s10565-019-09496-2. View

Yi Y, Hong W, Kang H, Kim H, Zhao W, Wang A . Inhibition of the PI3K/AKT pathway potentiates cytotoxicity of EGFR kinase inhibitors in triple-negative breast cancer cells. J Cell Mol Med. 2013; 17(5):648-56. PMC: 3822817. DOI: 10.1111/jcmm.12046. View

Sun X, Niu X, Chen R, He W, Chen D, Kang R . Metallothionein-1G facilitates sorafenib resistance through inhibition of ferroptosis. Hepatology. 2016; 64(2):488-500. PMC: 4956496. DOI: 10.1002/hep.28574. View

Zhang X, Sui S, Wang L, Li H, Zhang L, Xu S . Inhibition of tumor propellant glutathione peroxidase 4 induces ferroptosis in cancer cells and enhances anticancer effect of cisplatin. J Cell Physiol. 2019; 235(4):3425-3437. DOI: 10.1002/jcp.29232. View

Yu M, Gai C, Li Z, Ding D, Zheng J, Zhang W . Targeted exosome-encapsulated erastin induced ferroptosis in triple negative breast cancer cells. Cancer Sci. 2019; 110(10):3173-3182. PMC: 6778638. DOI: 10.1111/cas.14181. View

10.

Costa R, Han H, Gradishar W . Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review. Breast Cancer Res Treat. 2018; 169(3):397-406. DOI: 10.1007/s10549-018-4697-y. View

11.

Wenz C, Faust D, Linz B, Turmann C, Nikolova T, Dietrich C . Cell-cell contacts protect against t-BuOOH-induced cellular damage and ferroptosis in vitro. Arch Toxicol. 2019; 93(5):1265-1279. DOI: 10.1007/s00204-019-02413-w. View

12.

Khosravi-Shahi P, Cabezon-Gutierrez L, Aparicio Salcedo M . State of art of advanced triple negative breast cancer. Breast J. 2019; 25(5):967-970. DOI: 10.1111/tbj.13369. View

13.

Doll S, Proneth B, Tyurina Y, Panzilius E, Kobayashi S, Ingold I . ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol. 2016; 13(1):91-98. PMC: 5610546. DOI: 10.1038/nchembio.2239. View

14.

Cai H, Yang X, Gao Y, Xu Z, Yu B, Xu T . Exosomal MicroRNA-9-3p Secreted from BMSCs Downregulates ESM1 to Suppress the Development of Bladder Cancer. Mol Ther Nucleic Acids. 2019; 18:787-800. PMC: 6861677. DOI: 10.1016/j.omtn.2019.09.023. View

15.

Tang Q, Ouyang H, He D, Yu C, Tang G . MicroRNA-based potential diagnostic, prognostic and therapeutic applications in triple-negative breast cancer. Artif Cells Nanomed Biotechnol. 2019; 47(1):2800-2809. DOI: 10.1080/21691401.2019.1638791. View

16.

Girgert R, Emons G, Grundker C . 17β-estradiol-induced growth of triple-negative breast cancer cells is prevented by the reduction of GPER expression after treatment with gefitinib. Oncol Rep. 2016; 37(2):1212-1218. DOI: 10.3892/or.2016.5306. View

17.

McLaughlin R, He J, van der Noord V, Redel J, Foekens J, Martens J . A kinase inhibitor screen identifies a dual cdc7/CDK9 inhibitor to sensitise triple-negative breast cancer to EGFR-targeted therapy. Breast Cancer Res. 2019; 21(1):77. PMC: 6604188. DOI: 10.1186/s13058-019-1161-9. View

18.

Yang W, Sriramaratnam R, Welsch M, Shimada K, Skouta R, Viswanathan V . Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014; 156(1-2):317-331. PMC: 4076414. DOI: 10.1016/j.cell.2013.12.010. View

19.

von Pawel J . Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors. Bull Cancer. 2004; 91(5):E70-6. View

20.

Seibt T, Proneth B, Conrad M . Role of GPX4 in ferroptosis and its pharmacological implication. Free Radic Biol Med. 2018; 133:144-152. DOI: 10.1016/j.freeradbiomed.2018.09.014. View